标记临床研究 XOMA 深 沪
已收盘 08-01 16:00:00 美东时间
24.77
-0.110
-0.44%
华盛通- 最 高25.08
- 今 开24.51
- 成交量 2.08万股
- 最 低 24.0826
- 昨 收 24.88
- 总市值 2.96亿
- 52周最高 35.00
- 市盈率 静 --
- 换手率 0.17%
- 52周最低 18.352
- 委 比 65.99%
- 总股本 1196.69万
- 历史最高 191.40
- 量 比 1.05
- 振 幅 4.01%
- 历史最低 3.96
- 每 手 1
- 风险率 3.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多XOMA Royalty To Acquire Turnstone Biologics For $0.34 Per Share Plus CVR In August-Targeted Merger Deal
Pursuant and subject to the terms of the Merger Agreement, XOMA Royalty will commence a tender offer (the "Offer") by July 11, 2025, to acquire all outstanding shares of Turnstone common stock. The closing of the
06-27 19:33
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
XOMA Royalty Corporation will acquire Turnstone Biologics Corp. for $0.34 in cash per share plus one non-transferable contingent value right (CVR). The deal, approved by Turnstone's board, involves a tender offer to acquire all outstanding shares, with closing expected in August 2025. Leerink Partners and Cooley LLP are advising Turnstone, while Gibson, Dunn & Crutcher LLP is advising XOMA Royalty. Turnstone stockholders holding ~25.2% of shares ...
06-27 11:30
XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend
XOMA Corp - 8.375% DP PFD B (NASDAQ:XOMAO) declares $0.5234/share quarterly dividend, in line with previous. Forward yield 8.29% Payable July 15; for shareholders of record July 3; ex-div July 3. See ...
06-18 21:19
XOMA Preferred Shares Series A declares $0.539 dividend
XOMA Preferred Shares Series A (NASDAQ:XOMAP) declares $0.539/share quarterly dividend, in line with previous. Forward yield 8.41% Payable July 15; for shareholders of record July 3; ex-div July 3. Se...
06-18 21:19
XOMA Royalty Declares Quarterly Preferred Stock Dividends
XOMA Royalty Corporation announced cash dividends on its Series A and Series B Cumulative Preferred Stock. Series A holders will receive $0.53906 per share, while Series B depositary shares will receive $0.52344 per share. Dividends will be paid on July 15, 2025, to holders of record as of July 3, 2025. XOMA Royalty is a biotechnology royalty aggregator focused on acquiring future economic rights from therapeutic candidates, helping biotech compa...
06-18 11:30
美股大行评级 | 拼多多遭多家大行下调评级！Redburn Atlantic首予博通"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1134767544930545665.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持AnaptysBio(ANAB)"买入"评级，目标价从54美元升至90美元</p> <p>• Canaccord Genuity：维持Bridger Aerospace Gr(BAER)"买入"评
05-29 09:53
XOMA Royalty purchases mezagitamab royalty rights from BioInvent International for $30M
XOMA Royalty (NASDAQ:XOMA) and BioInvent International (BINV) said on Tuesday that XOMA Royalty has purchased the future mezagitamab royalty and milestone interests held by BioInvent for USD $20 mill...
05-27 20:47
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
XOMA Royalty Corporation purchased BioInvent International's future royalty and milestone interests in mezagitamab for $20 million, with a potential total of $30 million. The transaction enhances XOMA's portfolio and provides BioInvent non-dilutive capital to advance its pipeline. Mezagitamab, a Phase 3 anti-CD38 antibody, aims for best-in-class status in cancer immunotherapy.
05-27 12:01
美股大行评级 | 潜在涨幅89.34%！Loop Capital上调Warby Parker目标价至27美元，评级升至"买入"
每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。
04-18 08:48
美股大行评级 | Compass Point：上调Affirm Holdings评级至"买入"，目标价从61美元升至64美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1109399410911752193.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Femasys Inc Ordinary Shares(FEMY)"买入"评级，目标价从12美元升至15美元</p> <p>• HC Wainwright & C
03-20 09:49
